admin@ataxiatelangiectasia.es
Início
O que é A-T?
Notícias
Busca
News
Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial
Acessos: 210
EryDex
Quince Therapeutics
ChromaDex wins orphan designation for rare ataxia drug
Acessos: 326
EryDex
Nicotinamide Riboside
ChromaDex
FDA
Nanopore Long-Read Sequencing Facilitates Diagnosis of Atypical Ataxia-Telangiectasia
Acessos: 197
Korea
late onset variant
Nanopore
Neurology Genetics
IBEC and AEFAT join forces against ataxia telangiectasia
Acessos: 117
Spain
AEFAT
IBEC
Organoids to study ataxia telangiectasia
Acessos: 143
Spain
IBEC
organoids
Boston Children's Hospital lab trying to develop drug to treat boy's deadly rare disease
Acessos: 169
ASO
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Acessos: 80
EryDex
FDA
Quince Therapeutics
Governor of Queensland Celebrates Ataxia Telangiectasia Clinical Trial
Acessos: 110
Australia
Triheptanoin
Acasti reports results from ataxia telangiectasia therapy trial
Acessos: 219
GTX-102
Acasti Pharma
A New Model for Neurodegenerative Disease
Acessos: 121
pig model
Busca
Início
O que é A-T?
Notícias
admin@ataxiatelangiectasia.es